On Sunday, the genetic testing and heritage firm 23andMe introduced that it had entered Chapter 11 chapter and was asking a court docket to rearrange its sale. The corporate has been dropping cash for years, and a battle between its board and CEO about future instructions led to your entire board resigning again in September. Stated CEO, Anne Wojcicki, has now resigned and shall be pursuing an try to buy the corporate and take it non-public.
At stake is the destiny of genetic information from the corporate’s 15 million clients. The corporate has secured sufficient funding to proceed operations whereas a purchaser is discovered, and though US regulation limits how genetic information can be utilized, the pending sale has raised vital privateness considerations.
Dangerous enterprise
The corporate launched across the time that “gene chips” first allowed individuals to broadly scan the human genome for websites the place variations had been widespread. A number of of those variants are related to illnesses, and 23andMe obtained approval to check for a lot of these. However its large promoting level for many individuals was the chance to discover their heritage. This relied on trying broadly on the patterns of variation and evaluating these to the patterns usually discovered in several geographic areas. It’s an imperfect evaluation, however it may usually present a good big-picture decision of an individual’s ancestry.
23andMe confronted a lot of challenges, although. For starters, the gene chips rapidly grew to become commodities, permitting a wide range of rivals to enter the sphere, a few of which had stronger backgrounds in issues like linking genealogies to public information. This commodification additionally meant that many potential 23andMe companions within the pharmaceutical business, who is perhaps concerned with gene/illness linkages, might affordably construct their very own databases or just depend on a number of the public assets which have since been developed, just like the UK’s Biobank.